ArticleJournal of biological engineering2025
Bioengineered injectable HAMA/GelMA hydrogel encapsulating exosomes loaded lycopene mitigates deoxynivalenol-induced testicular injury via apoptotic pathway modulation.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hydrogels: current biomedical applications and future directions.Molecular biomedicine · 2026Review
- Next-Generation Hydrogels Integrating Natural Antioxidants and Microbiome Modulators for Improved Cancer Management.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Deoxynivalenol (Dex), a widespread mycotoxin found in contaminated cereals, induces testicular dysfunction primarily through oxidative stress, inflammation, and activation of apoptotic pathways. Lycopene (Lyc), a natural antioxidant, offers cytoprotective potential but is limited by poor aqueous solubility and instability. To address these limitations, we developed a bioengineered injectable hydrogel system composed of hyaluronic acid and gelatin methacrylate, both natural biopolymers, to encapsulate exosomes preloaded with lycopene (HAMA-GelMA@Exo-Lyc) for controlled, localized delivery. Comprehensive characterization demonstrated successful integration of HAMA-GelMA@Exo-Lyc hydrogel, evidenced by a shifted amide I band at 1643.67 cm⁻¹ and a uniform porous network of 50-150 μm. The modified hydrogel exhibited improved mechanical strength (21.8 ± 1.6 kPa), faster gelation (95 ± 8 s), and enhanced water retention (85.7 ± 3.1%) compared to the unmodified HAMA/GelMA system. In vitro, GC-1 spg cells treated with HAMA-GelMA@Exo-Lyc hydrogel exhibited enhanced viability, maintaining over 79.0 ± 0.30% cell survival at 150 µg/mL after 24 h, alongside reduced ROS levels and improved proliferative capacity compared to free Lyc. In a Dex-induced testicular injury model, HAMA/GelMA@Exo-Lyc treatment restored serum testosterone levels, improved spermatogenic architecture, and significantly reduced oxidative stress markers. Elevated levels of GSH and CAT indicated an enhanced antioxidant defense, whereas reductions were noted in inflammatory mediators TNF-α and IL-1β, as well as in mitochondrial apoptosis-associated proteins, such as Cyt-c, Bax, and Caspase-3. Meanwhile, Bcl-2 expression rose, suggesting anti-apoptotic effects. These results suggest that HAMA-GelMA@Exo-Lyc represents a promising bioengineered platform for mitigating Dex-induced testicular damage by suppressing oxidative stress and modulating the apoptosis pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.